Board of directors

 

   

Göran Ando
Chairman of the Board of Directors

Dr. Ando was CEO of Celltech Group plc, UK, until 2004. He joined Celltech from Pharmacia, now Pfizer, where he was Executive Vice President and President of R&D with additional responsibilities for manufacturing, IT, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, Dr. Ando was Medical Director, moving to Deputy R&D Director and then R&D Director of Glaxo Group, UK. He was also a member of the Glaxo Group Executive Committee. Dr. Ando serves as Chairman of Novo Nordisk A/S, and as board member of Novo Holdings A/S, Molecular Partners AG, and EUSA Pharma and ICMEC (International Centre for Missing and Exploited Children). He also serves as a Senior Advisor to Essex Woodlands Health Ventures UK Ltd. Dr. Ando is a Specialist in General Medicine and is a Founding Fellow of the American College of Rheumatology in the U.S. Dr. Ando serves as Chairman of Symphogen's Remuneration Committee.

   

Kirsten Drejer, M.Sc., Ph.D.
Co-founder and CEO of Symphogen from 2000-2016
Kirsten Drejer has 30 years of experience in the pharmaceutical and biotech industry. Before joining Symphogen, Dr. Drejer held several scientific and managerial positions in Novo Nordisk including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. Since 2000, co-founder and CEO of Symphogen until September 2016. Dr. Drejer is a Board member of Symphogen, The Fund for Industrial Growth, Bioneer, Bioporto & Lyhne & Co.
She is on the Advisory Board for The Faculty of Pharmaceutical Sciences, University of Copenhagen and  the Entrepreneurship Advisory Board at Copenhagen Business School. She is a  member of the Executive Management group VL-42 and The Danish Academy of Technical Sciences. She is a NOME mentor in Nordic Mentor Network for Entrepreneurship. She was awarded the ‘BiotechBuilder of the Year' prize in 2003, ‘Entrepreneur of the Year, Biotech' in 2007, and portrayed as top women in biotech 2013 by Fierce Biotech

 

   
Ron Eastman, MBA
Mr. Eastman, Managing Director of Essex Woodlands, has over 30 years of experience in building healthcare businesses. Mr. eastman began his career at American Cyanamid Company, where he spent 15 years managing pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, Mr. Eastman has helped build three private healthcare companies - Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron became a cutting-edge biotech company which grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer.  HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. At Rinat, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders.  Rinat was acquired by Pfizer for $500M in 2006. Mr. Eastman serves on the boards of Corium International, EluSys Therapeutics, Inc., IntegenX Inc., Open Monoclonal Technology, Inc. ("OMT"), Protein Simple and Revance Therapeutics, Inc. He holds a Bachelor of Arts from Williams College and a Master of Business Administration degree from Columbia University. Mr. Eastman serves as a member of Symphogen's Remuneration Committee.
 
   

Jeppe Christiansen, M.Sc. 
Mr. Christiansen holds a M.Sc. (Economy) from the University of Copenhagen. Jeppe Christiansen is Chief Executive Officer of Maj Invest A/S, of which he is also a co-founder and Maj Invest Holding A/S. Mr. Christiansen is member of the Executive Management of Maj Invest Equity A/S, Denmark and Vice Chairman of Maj Bank A/S. From 1986 to 1988, he worked as an economist in Sparekassen SDS. He came to LD Pensions in 1988 where he became Head of Fund Management and later Executive Vice President responsible for investments. From 1998 to 2004, Mr. Christiansen worked as Director in Danske Bank, responsible for international equity investments and corporate clients. Mr. Christiansen is Chairman of the of Board Haldor Topsøe A/S, Vice Chairman of the Board of Novo Nordisk A/S, and a member of the board of directors of Novo Holdings A/S, Kirkbi A/S, Det Kgl. Vajsenhus and Emlika ApS. Mr. Christiansen serves as  as a member of Symphogen's Remuneration  Committee.
 
 

 

John B. Landis, Ph.D.
Dr. Landis joined the Bioanalytical Systems Inc. (BASi) Board of Directors in November 2009 and was elected Chairman of the Board on February 11, 2010. Dr. Landis previously served as Senior Vice President of Pharmaceutical Sciences of Schering-Plough Corporation, from 2003 until his retirement in 2008. Dr. Landis led the global pharmaceutical sciences function of pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, clinical supplies and devices. Dr. Landis holds Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from Kent State University. Dr. Landis serves as Chairman of Symphogen's Development Committee.

 
   
     

Anthony Tolcher, MD FRCPC FACP
President and Co-Founder of START
Dr. Tolcher is a medical oncologist with over 20 years' experience in early drug development and clinical trials. He has been involved in many of the initial studies of new agents that were subsequently FDA approved for the treatment of cancer including Keytruda® (pembroli- zumab), Kadcyla® (trastuzumab emtansine), Stivarga® (regorafenib), Marqibo® (liposomal vincristine), Jevtana® (cabazitaxel), Kyprolis® (carfilzomib), Iressa® (gefitinib), Tarceva® (erlotinib), and Halaven® (eribulin). He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program and is on many pharmaceutical company scientific advisory boards. Dr. Tolcher is the president and co-founder of the START clinic in Texas, the US. Dr. Tolcher serves as a member of Symphogen's  Development Committee.

 

   

Jeffrey H. Buchalter, MBA 

Mr. Buchalter has over 30 years experience in the bio/pharmaceuti- cal industry. His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organizations. He brings extensive commercial and drug development experience in oncology and other therapeutic areas. Jeffrey has been recognized for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field. He has also been a Collaborating Partner in the President's National Dialogue on Cancer and acted as Chair- man of the Board of Directors to the National Childhood Cancer Foundation in the United States. Jeffrey received Bachelor Degrees in both Science and Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University. Jeffrey H. Buchalter serves as Chairman of Symphogen's Audit Committee and a member of Symphogen's Development Committee.

 

 

   

Christoffer Søderberg, MSc in Finance and Accounting 

Mr. Søderberg is a Senior Director in Novo Large Investments, leading investment processes and taking part in managing and developing the portfolio of investments. Prior to joining Novo Holdings A/S, he was a Senior Principal at the Boston Consulting group (BCG) leading the Copenhagen Private Equity and Principal Investors practice area.. Prior to joining BCG, Mr. Søderberg worked at Falck A/S as Global Head of group Strategy and M&A, and most recently as CFO of Falck Assistance. Prior to joining Falck, he worked as a Director at Carnegie Investment Banking focusing on buy- and sell-side M&A. Mr. Søderberg holds a BSc in International Business and an MSc in Finance and Accounting from the Copenhagen Business School. Mr. Søderberg serves as a member of Symphogen's Audit Committee..